Disclaimer: This information is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. It is intended for use by healthcare professionals and should be used in conjunction with their clinical judgment. Treatment decisions must always be made based on individual patient circumstances, current clinical guidelines, and consultation with appropriate specialists. Drug dosages and regimens are subject to change and should be verified with official prescribing information and current guidelines.

Anaplastic Lymphoma

Overview

• Definition: Anaplastic Lymphoma, specifically Anaplastic Large Cell Lymphoma (ALCL), is a rare, aggressive type of mature T-cell non-Hodgkin lymphoma characterized by the proliferation of large, pleomorphic cells with horseshoe-shaped or kidney-shaped nuclei that strongly and uniformly express CD30. It can be broadly categorized into systemic ALCL and primary cutaneous ALCL, and Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).
• Epidemiology:
  • Represents approximately 2-8% of all adult non-Hodgkin lymphomas (NHL) and 10-30% of pediatric NHL.
  • Systemic ALCL: Has a bimodal age distribution, with peaks in childhood/adolescence and in individuals over 60 years. More common in males.
  • Primary Cutaneous ALCL (pcALCL): Primarily affects older adults, with a median age of 60 years. More common in males.
  • Breast Implant-Associated ALCL (BIA-ALCL): Rare, exclusively associated with breast implants (primarily textured implants).
• Classification:
  • Systemic ALCL:
    • ALK-positive (ALK+) ALCL: Accounts for 60-80% of systemic ALCL cases. Characterized by a chromosomal translocation involving the ALK gene (most commonly t(2;5)(p23;q35) leading to NPM1-ALK fusion). Generally has a better prognosis than ALK-negative ALCL.
    • ALK-negative (ALK-) ALCL: Accounts for 20-40% of systemic ALCL cases. Lacks ALK gene rearrangements. This is a more heterogeneous group, often associated with other genetic aberrations (e.g., DUSP22 rearrangements, TPM3-ALK fusion, or JAK1/STAT3 pathway activation) and typically has a worse prognosis than ALK+ ALCL.
  • Primary Cutaneous ALCL (pcALCL): Confined to the skin at diagnosis, with no evidence of extracutaneous disease. Typically an indolent course, even though it can present with aggressive histopathological features. It is ALK-negative.
  • Breast Implant-Associated ALCL (BIA-ALCL): A distinct lymphoma arising in the periprosthetic capsule or seroma fluid surrounding breast implants. It is ALK-negative and generally has an excellent prognosis when managed appropriately.

Pathophysiology

• Mechanism:
  • Systemic ALK+ ALCL: The hallmark is a chromosomal translocation involving the ALK gene on chromosome 2p23, most commonly t(2;5)(p23;q35) leading to the NPM1-ALK fusion gene. This fusion results in constitutive activation of the ALK tyrosine kinase, leading to uncontrolled cell proliferation, inhibition of apoptosis, and cellular transformation through activation of downstream signaling pathways (e.g., JAK/STAT, PI3K/AKT, MAPK/ERK).
  • Systemic ALK- ALCL: Lacks the ALK rearrangement. Pathogenesis is more diverse and less understood. Common genetic alterations include rearrangements of DUSP22 (on 6p25.3) or TPM3-ALK fusion variants, and frequently involves mutations or deletions affecting genes in the JAK/STAT pathway (e.g., JAK1, STAT3, SOCS1). These lead to constitutive activation of survival pathways.
  • Primary Cutaneous ALCL: The pathogenesis is not fully elucidated, but it is distinct from systemic ALCL. It is ALK-negative. Genomic studies suggest recurrent mutations in STAT3 and other epigenetic regulators. Chronic antigenic stimulation and immune dysregulation are implicated.
  • BIA-ALCL: Believed to be driven by chronic inflammation and immune stimulation related to the presence of breast implants (especially textured surfaces leading to bacterial biofilm formation). This chronic stimulation is thought to drive T-cell proliferation and potentially leads to JAK/STAT pathway activation, promoting lymphomagenesis in a susceptible individual.
• Risk Factors:
  • Systemic ALCL: Largely idiopathic. No strong, consistent environmental or genetic risk factors identified. Immunosuppression (e.g., post-transplant, HIV) is a general risk factor for various lymphomas, but less specifically for ALCL subtypes.
  • Primary Cutaneous ALCL: No specific risk factors identified.
  • BIA-ALCL: The most significant and well-established risk factor is the presence of textured breast implants. The risk is correlated with the degree of surface texturization (higher texturization, higher risk). The exact mechanism linking textured implants to ALCL is still under investigation but involves chronic inflammation and potentially bacterial biofilms.
• Protective Factors: None definitively established for any subtype of ALCL. For BIA-ALCL, using smooth breast implants rather than textured implants theoretically reduces risk, though smooth implants are not entirely risk-free.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Systemic ALCL: Rapidly growing, painless peripheral lymphadenopathy (neck, axilla, groin) is most common.
  • B symptoms: Fever (unexplained, >38°C), drenching night sweats, and unexplained weight loss (>10% body weight in 6 months) are common, occurring in 50-70% of cases.
  • Extranodal involvement: Common (up to 70-80% of cases), including skin, bone, soft tissue, lung, liver, spleen, and gastrointestinal tract. Skin lesions can mimic pcALCL.
  • Primary Cutaneous ALCL: Typically presents as solitary or localized multiple cutaneous nodules, tumors, or plaques. Ulceration may occur. Lesions can spontaneously regress in some cases. Generally not associated with B symptoms or systemic involvement.
  • BIA-ALCL: Most commonly presents as a late-onset unilateral seroma (fluid collection) around the breast implant, typically 7-10 years post-implantation (range: 2-30 years). Less commonly, it presents as a breast mass, capsular contracture, skin rash, or axillary lymphadenopathy. B symptoms are uncommon but can occur in advanced cases.
• Early Signs:
  • Systemic ALCL: Localized, rapidly enlarging lymph node.
  • pcALCL: Solitary skin nodule or plaque.
  • BIA-ALCL: Unilateral breast swelling or change in breast size/shape due to seroma.
• Advanced Signs:
  • Systemic ALCL: Widespread lymphadenopathy, significant extranodal disease, cytopenias, effusions (pleural, pericardial, ascites), signs of organ dysfunction (e.g., liver failure, respiratory compromise).
  • pcALCL: Multiple widespread skin lesions, though systemic spread is rare.
  • BIA-ALCL: Palpable breast mass (involving capsule or breast parenchyma), regional lymphadenopathy (axillary), rare systemic spread.
• Atypical Presentations:
  • Systemic ALCL: Mimicry of infectious mononucleosis (especially in children), hemophagocytic lymphohistiocytosis (HLH)-like syndrome (fever, hepatosplenomegaly, cytopenias, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis), leukemic presentation (rare, with circulating CD30+ cells).
  • pcALCL: Spontaneous regression of lesions can occur, leading to diagnostic confusion or delayed diagnosis if not biopsied.
  • BIA-ALCL: Can be misdiagnosed as late seroma due to infection or rupture.

Physical Examination

• Inspection:
  • Lymphadenopathy: Size, location (cervical, axillary, inguinal).
  • Skin: Macules, papules, plaques, nodules, tumors; ulceration; color changes; rash. Look for characteristic lesions of pcALCL or extranodal systemic ALCL.
  • Breast: Asymmetry, swelling, skin changes (redness, dimpling), visible mass, or fluid collection around implants.
  • Abdomen: Distention (ascites), jaundice.
  • General: Signs of weight loss, pallor, petechiae/purpura.
• Palpation:
  • Lymph nodes: Assess size, consistency (rubbery, firm), mobility, tenderness.
  • Abdomen: Hepatosplenomegaly, palpable masses.
  • Bones: Tenderness (bone involvement).
  • Breast: Palpable seroma, mass, or thickened capsule around implants.
• Special Tests: No specific special tests for ALCL on physical examination.

Diagnostic Approach

History Taking

• Key Questions:
  • Systemic Symptoms: Presence and duration of B symptoms (fevers, night sweats, weight loss).
  • Lymphadenopathy: Onset, size, progression, pain.
  • Extranodal Symptoms: Skin lesions (onset, evolution), bone pain, respiratory symptoms (cough, dyspnea), abdominal pain, neurological symptoms.
  • Past Medical History: Immunosuppression (HIV, organ transplant), autoimmune conditions.
  • Medications: Immunosuppressants.
  • Breast Implants: Presence of breast implants (type, date of insertion), onset and nature of breast symptoms, prior breast surgeries.
  • General: Performance status, fatigue.
• Red Flags:
  • Rapidly enlarging lymphadenopathy or masses.
  • Unexplained B symptoms.
  • New onset unilateral breast swelling or palpable mass around an implant.
  • Signs of spinal cord compression (weakness, numbness, bowel/bladder dysfunction).
  • Signs of superior vena cava (SVC) syndrome (facial/neck swelling, dyspnea, prominent superficial chest veins).

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC) with differential: To assess for anemia, leukopenia, thrombocytopenia, or lymphocytosis. May reveal cytopenias from bone marrow involvement or HLH.
  • Liver Function Tests (LFTs): To assess for hepatic involvement or dysfunction.
  • Renal Function Tests (RFTs): Blood urea nitrogen (BUN), creatinine, electrolytes.
  • Lactate Dehydrogenase (LDH): Often significantly elevated in aggressive lymphomas, a prognostic marker.
  • Uric Acid: May be elevated, especially with high tumor burden (risk of tumor lysis syndrome).
  • Beta-2 Microglobulin (β2M): A non-specific tumor marker, elevated in many lymphomas, correlates with tumor burden.
  • Erythrocyte Sedimentation Rate (ESR) / C-Reactive Protein (CRP): Inflammatory markers, often elevated.
  • Viral Serologies: HIV, Hepatitis B (HBV), Hepatitis C (HCV) due to implications for treatment.
• Confirmatory:
  • Excisional Biopsy (Lymph node or involved extranodal tissue): This is paramount for diagnosis. Fine Needle Aspiration (FNA) is generally insufficient for definitive diagnosis due to architectural distortion and limited tissue for immunophenotyping and molecular studies. Core needle biopsy may be acceptable if excisional biopsy is not feasible, but it carries higher risk of non-diagnostic results.
  • Histopathology: Large, pleomorphic cells, often with horseshoe- or kidney-shaped nuclei and abundant cytoplasm. Hallmark cells and scatter pattern are characteristic.
  • Immunohistochemistry (IHC):
    • CD30: Strong and uniform membrane and Golgi pattern positivity is the defining characteristic of ALCL cells.
    • ALK: Staining for ALK protein. Positive in ALK+ ALCL, negative in ALK- ALCL, pcALCL, and BIA-ALCL.
    • T-cell markers: CD3 (often negative or weak in ALCL), CD2, CD5, CD7 (often aberrant or lost expression). CD4 is often positive.
    • Other markers: EMA (often positive), perforin, granzyme B (often positive, particularly in ALK+ ALCL), cytotoxic molecules. PAX5 (negative), CD20 (negative).
  • Molecular Studies:
    • FISH (Fluorescence In Situ Hybridization): To detect ALK gene rearrangements (e.g., t(2;5)) in systemic ALCL.
    • RT-PCR (Reverse Transcriptase Polymerase Chain Reaction): To detect ALK fusion transcripts.
    • Next-Generation Sequencing (NGS): May be used to identify other recurrent genetic alterations (e.g., DUSP22 rearrangements, STAT3 mutations).
  • BIA-ALCL specific: Cytology and flow cytometry of periprosthetic fluid (seroma) for CD30+ cells. Cell block of fluid for IHC. Biopsy of capsule if a mass is present.
• Monitoring:
  • LDH and CBC: For disease activity and treatment response.
  • Imaging: As described below.

Imaging

• Recommended:
  • PET-CT (Positron Emission Tomography-Computed Tomography): Standard for initial staging of systemic ALCL (identifies all metabolically active lesions, including lymph nodes and extranodal sites, and assesses response to therapy).
  • CT Chest, Abdomen, Pelvis (with IV contrast): If PET-CT is unavailable or contraindicated, for staging of systemic disease.
  • MRI (Magnetic Resonance Imaging): For specific sites of involvement, e.g., brain/spinal cord if neurological symptoms present, or detailed assessment of bone involvement.
  • Breast Ultrasound/MRI for BIA-ALCL: To characterize fluid collections or masses around breast implants. MRI with and without contrast is preferred for extent of disease.
• Advanced:
  • Bone Marrow Biopsy: Essential for staging of systemic ALCL to rule out bone marrow involvement (trephine biopsy and aspirate with IHC for CD30/ALK).
  • Lumbar Puncture (LP): If neurological symptoms or high-risk features for CNS involvement (e.g., testicular involvement, high LDH). Cytology and flow cytometry for malignant cells.

Management

Acute Management

• Immediate:
  • Address life-threatening complications: Superior Vena Cava (SVC) syndrome, spinal cord compression, tumor lysis syndrome.
  • Symptomatic control: Pain management, antiemetics, fever reduction.
• Stabilization:
  • Initiate appropriate chemotherapy or radiation therapy urgently for rapidly progressive disease or impending organ compromise.
  • Fluid management and allopurinol for prevention of tumor lysis syndrome in high-risk patients.
  • Blood product transfusions for significant cytopenias.
• Emergency:
  • SVC Syndrome: Emergent radiation therapy or chemotherapy (e.g., corticosteroids initially, then specific chemotherapy).
  • Spinal Cord Compression: High-dose corticosteroids (e.g., dexamethasone 10 mg IV stat, then 4 mg Q6H) and urgent imaging, followed by emergent radiation or surgery.
  • Tumor Lysis Syndrome: Aggressive hydration, allopurinol or rasburicase, correction of electrolyte imbalances.
  • Severe Bleeding/Infection: Prompt management with transfusions or broad-spectrum antibiotics and growth factors.

Chronic Management

• Pharmacological:
  • Systemic ALK+ ALCL:
    • First-line:
      • Brentuximab Vedotin (BV) + CHP (cyclophosphamide, doxorubicin, prednisone): BV (1.8 mg/kg IV) on day 1 with CHP (cyclophosphamide 750 mg/m², doxorubicin 50 mg/m² on day 1, prednisone 100 mg orally on days 1-5) every 21 days for 6 cycles. This is now the preferred frontline regimen based on the ECHELON-2 trial, demonstrating superior progression-free survival (PFS) and overall survival (OS) compared to CHOP.
      • CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone): Cyclophosphamide 750 mg/m² IV day 1, Doxorubicin 50 mg/m² IV day 1, Vincristine 1.4 mg/m² (max 2 mg) IV day 1, Prednisone 100 mg/day PO days 1-5. Administered every 21 days for 6-8 cycles. Remains an option, especially if BV+CHP is unavailable or contraindicated.
    • Relapsed/Refractory:
      • ALK inhibitors: Crizotinib (250 mg PO BID), Alectinib, Brigatinib. Highly effective for ALK+ disease.
      • Brentuximab Vedotin (BV): 1.8 mg/kg IV every 3 weeks.
      • Other options: Gemcitabine (1000 mg/m² IV days 1, 8), Bendamustine (90-120 mg/m² IV days 1, 2), platinum-based regimens (e.g., ICE: Ifosfamide, Carboplatin, Etoposide), clinical trials.
      • Autologous Stem Cell Transplant (ASCT): Considered for patients achieving remission after salvage therapy for relapsed/refractory disease.
  • Systemic ALK- ALCL:
    • First-line:
      • CHOP: Similar to ALK+ ALCL, 6-8 cycles.
      • BV + CHP: Emerging as a preferred frontline option as well, showing similar benefits to CHOP (though ECHELON-2 included a small subset of ALK- patients).
    • Relapsed/Refractory:
      • Brentuximab Vedotin (BV): 1.8 mg/kg IV every 3 weeks.
      • PD-1 inhibitors: Nivolumab (3 mg/kg IV every 2 weeks or 240 mg IV every 2 weeks), Pembrolizumab (200 mg IV every 3 weeks) - emerging data for efficacy.
      • Other options: Gemcitabine, Bendamustine, platinum-based regimens, clinical trials.
      • ASCT: For eligible patients in remission after salvage.
      • Allogeneic Stem Cell Transplant (alloSCT): May be considered for select young, fit patients with relapsed/refractory disease.
  • Primary Cutaneous ALCL (pcALCL):
    • Localized disease:
      • Surgical Excision: For small, solitary lesions.
      • Radiotherapy: For solitary or localized multiple lesions, typically 30-36 Gy in 15-18 fractions.
    • Multiple/Widespread/Recurrent disease:
      • Low-dose Methotrexate: 15 mg PO/IM weekly. Often used for widespread but indolent pcALCL.
      • Brentuximab Vedotin (BV): 1.8 mg/kg IV every 3 weeks. Highly effective, especially for refractory or widespread cases.
      • Systemic Chemotherapy (e.g., CHOP): Reserved for patients with rapidly progressive, very widespread, or refractory pcALCL, or those with extracutaneous spread (which then indicates systemic ALCL).
  • Breast Implant-Associated ALCL (BIA-ALCL):
    • Primary Treatment: Complete surgical excision of the implant and the entire fibrous capsule (total capsulectomy), ideally en bloc (removing implant and capsule as one piece). This is curative in most cases.
    • Adjuvant Therapy: Typically not required if disease is confined to the capsule and completely resected.
    • Chemotherapy/Radiotherapy: For patients with residual disease after surgery, positive lymph nodes, invasion into breast tissue, or distant metastatic disease. Regimens often include CHOP or BV+CHP. Radiation may be considered for local residual disease.
• Non-pharmacological:
  • Supportive Care: Anti-emetics, growth factors (G-CSF for neutropenia), blood transfusions, pain control, nutritional support.
  • Psychosocial Support: Counseling, support groups.
  • Fertility Preservation: Discuss options before chemotherapy.
• Monitoring:
  • During Treatment: Regular CBC, LFTs, RFTs, electrolytes to monitor for toxicity. LDH for response.
  • Post-Treatment:
    • Clinical evaluation: Physical exam every 3-6 months for 2 years, then annually for at least 5 years.
    • Laboratory: CBC, LDH, chemistry panel.
    • Imaging: PET-CT or CT scans every 3-6 months for 2 years, then less frequently as indicated (e.g., annually for a few more years, or as clinically indicated). For pcALCL, clinical follow-up and photography of lesions suffice for surveillance; imaging only if systemic spread suspected. For BIA-ALCL, post-operative imaging (MRI/US) for follow-up as clinically indicated.

Treatment Algorithms

• First-Line:
  • Systemic ALK+ ALCL (Adults): Brentuximab Vedotin + CHP (preferred) or CHOP x 6-8 cycles.
  • Systemic ALK- ALCL (Adults): CHOP or Brentuximab Vedotin + CHP x 6-8 cycles.
  • Pediatric ALCL (predominantly ALK+): A-BVP (doxorubicin, bleomycin, vincristine, prednisone), COG ANHL0131 protocol, or specific pediatric ALCL protocols. BV+CHP is also being explored in pediatric trials.
  • Primary Cutaneous ALCL: Localized: Excision or Radiation. Widespread/Recurrent: Low-dose Methotrexate or Brentuximab Vedotin.
  • BIA-ALCL: Complete surgical excision of implants and capsule (en bloc total capsulectomy).
• Second-Line (Relapsed/Refractory Systemic ALCL):
  • ALK+ ALCL: ALK inhibitors (crizotinib, alectinib), Brentuximab Vedotin, multi-agent salvage chemotherapy (e.g., ICE, DHAP, GDP), followed by ASCT in eligible patients achieving remission.
  • ALK- ALCL: Brentuximab Vedotin, PD-1 inhibitors (nivolumab, pembrolizumab), multi-agent salvage chemotherapy (e.g., ICE, DHAP, GDP), followed by ASCT in eligible patients achieving remission. AlloSCT may be considered in selected high-risk or multiply relapsed patients.
• Refractory Cases:
  • Consider enrollment in clinical trials investigating novel agents (e.g., novel ALK inhibitors, other targeted agents, CAR T-cell therapy in specific settings, if available).
  • Palliative care and symptom management.

Complications

• Common:
  • Chemotherapy-related: Myelosuppression (neutropenia, anemia, thrombocytopenia), febrile neutropenia, nausea, vomiting, fatigue, alopecia, mucositis.
  • Vincristine-related: Peripheral neuropathy (sensory and motor).
  • Brentuximab Vedotin-related: Peripheral neuropathy (cumulative dose-dependent), neutropenia, fatigue.
  • Doxorubicin-related: Cardiotoxicity (dose-dependent).
• Serious:
  • Infections: Due to neutropenia and immunosuppression (bacterial, viral, fungal, opportunistic).
  • Tumor Lysis Syndrome: Metabolic derangements (hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) leading to acute kidney injury, arrhythmias.
  • Superior Vena Cava (SVC) Syndrome: Due to mediastinal lymphadenopathy.
  • Spinal Cord Compression: Due to epidural involvement.
  • Secondary Malignancies: Myelodysplastic syndromes (MDS)/Acute Myeloid Leukemia (AML) following genotoxic chemotherapy.
  • Anaphylaxis/Infusion Reactions: To chemotherapy agents or monoclonal antibodies.
• Long-term:
  • Peripheral Neuropathy: May be persistent or slowly resolving after vincristine or brentuximab vedotin.
  • Cardiotoxicity: From anthracyclines (doxorubicin), leading to cardiomyopathy.
  • Infertility: Due to gonadotoxic effects of chemotherapy (especially alkylating agents).
  • Hypothyroidism: If neck region irradiated.
  • Psychosocial Impact: Chronic fatigue, anxiety, depression, fear of recurrence.

Prognosis

• Factors:
  • ALK status: The most significant prognostic factor for systemic ALCL. ALK+ ALCL generally has a much better prognosis than ALK- ALCL.
  • International Prognostic Index (IPI): A composite score based on age (>60 years), performance status (ECOG >1), LDH (elevated), extranodal sites (≥2), and stage (III/IV). Higher IPI score indicates worse prognosis.
  • Stage: Advanced stage (III/IV) is associated with poorer prognosis.
  • Age: Younger patients, especially children with ALK+ ALCL, tend to have better outcomes.
  • Performance Status: Poor performance status negatively impacts prognosis.
  • Bone Marrow Involvement: Presence of bone marrow involvement indicates advanced disease and is a negative prognostic factor.
  • Genetic/Molecular markers: For ALK- ALCL, rearrangements of DUSP22 or mutations in STAT3 may correlate with better outcomes, while other complex karyotypes or TP53 mutations indicate worse prognosis.
• Survival:
  • Systemic ALK+ ALCL: Generally good prognosis. 5-year Overall Survival (OS) rates are typically 70-80% in adults and even higher in children (>80-90%).
  • Systemic ALK- ALCL: Worse prognosis than ALK+ ALCL. 5-year OS rates are typically 40-50% in adults, but can vary widely depending on specific molecular features.
  • Primary Cutaneous ALCL (pcALCL): Excellent prognosis. Generally indolent with frequent spontaneous regressions. 5-year OS rates typically exceed 90-95%. Relapses are common but usually localized to the skin. Transformation to systemic lymphoma is rare.
  • Breast Implant-Associated ALCL (BIA-ALCL): Excellent prognosis when treated with complete surgical excision of the implant and capsule. 5-year OS rates are typically >90% for localized disease. If advanced or disseminated, prognosis is poorer but still better than typical systemic ALCL with similar staging.
• Quality of Life: Can be significantly impacted by treatment side effects (e.g., fatigue, peripheral neuropathy, hair loss, gastrointestinal issues) and long-term sequelae of therapy. Early and comprehensive supportive care, including psychosocial support, is crucial.

Prevention

• Primary:
  • Systemic ALCL: No specific primary prevention strategies are known due to the idiopathic nature of most cases.
  • BIA-ALCL: Avoiding textured breast implants would reduce the risk of BIA-ALCL. However, smooth implants are not entirely risk-free, and patient choice for implant type must be balanced with the very low, albeit present, risk.
• Secondary:
  • Early detection: Prompt evaluation and biopsy of unexplained, persistent lymphadenopathy, suspicious skin lesions, or new-onset seromas/masses around breast implants. Early diagnosis and treatment can improve outcomes, particularly for systemic ALCL.
  • Awareness: Education of healthcare providers and patients regarding the symptoms of BIA-ALCL to facilitate early diagnosis.
• Tertiary:
  • Prevention of complications: Proactive management of chemotherapy side effects, surveillance for late effects, and monitoring for relapse.
  • Long-term follow-up: Regular clinical and imaging surveillance as per guidelines to detect recurrence early.

Special Populations

• Pediatric:
  • ALK+ ALCL is the most common subtype in children and generally has a better prognosis than in adults.
  • Treatment regimens are often adapted to minimize long-term toxicities (e.g., reduced anthracycline exposure, emphasis on protocols with more tolerable long-term profiles).
  • Specific cooperative group protocols (e.g., from Children's Oncology Group - COG) are used.
• Geriatric:
  • Increased prevalence of comorbidities, reduced organ function (renal, cardiac), and decreased tolerance to aggressive chemotherapy.
  • Dose modifications or use of less intensive regimens may be necessary.
  • Careful assessment of fitness (e.g., comprehensive geriatric assessment) is crucial to guide treatment decisions.
  • Increased risk of treatment-related mortality and severe adverse events.
• Pregnancy:
  • Extremely rare. Diagnosis and management are highly complex, requiring multidisciplinary input (oncologist, maternal-fetal medicine, neonatologist).
  • Chemotherapy is generally avoided in the first trimester due to teratogenicity risk.
  • Treatment may be delayed until the second or third trimester or post-delivery if possible.
  • Specific chemotherapy agents pose different risks (e.g., anthracyclines are often used in the second/third trimester with caution; vincristine considered safer than alkylating agents or antimetabolites).
  • Radiation therapy is generally contraindicated due to fetal exposure.
• Comorbidities:
  • Renal/Hepatic Impairment: Requires dose adjustments for renally or hepatically excreted drugs (e.g., doxorubicin, cyclophosphamide, methotrexate, brentuximab vedotin).
  • Cardiac Disease: Careful monitoring of cardiac function (echocardiogram) before and during treatment with anthracyclines (doxorubicin); consider liposomal doxorubicin or dose reduction.
  • Pre-existing Neuropathy: Vincristine and brentuximab vedotin can exacerbate neuropathy; careful monitoring and potential dose modification or discontinuation.
  • Immunosuppression (e.g., HIV, post-transplant): Increased risk of opportunistic infections. Careful antimicrobial prophylaxis. Treatment regimens may need adaptation.

Clinical Pearls

• Diagnostic:
  • Always obtain an excisional biopsy of the involved lymph node or tissue; FNA is insufficient for definitive diagnosis of ALCL.
  • CD30 strong and uniform expression is key: It's the defining immunohistochemical marker. However, CD30 can be expressed in other lymphomas (e.g., classical Hodgkin lymphoma, some DLBCL), requiring a full panel for differentiation.
  • ALK status is critical: Determine ALK expression by IHC and ALK rearrangement by FISH/RT-PCR, as it dictates prognosis and treatment approach for systemic ALCL.
  • Consider ALCL in B symptoms and extranodal disease: Especially with skin involvement.
  • BIA-ALCL requires high index of suspicion: Any late-onset seroma or mass around a breast implant should prompt evaluation for BIA-ALCL, including cytology of fluid for CD30+ cells.
• Treatment:
  • BV+CHP is now the preferred frontline regimen for systemic ALCL (especially ALK+) over CHOP due to superior outcomes and tolerability in the ECHELON-2 trial.
  • ALK inhibitors are highly effective for relapsed/refractory ALK+ ALCL.
  • Complete surgical excision is curative for localized BIA-ALCL.
  • pcALCL is often indolent: Localized therapy (surgery/radiation) is sufficient for most cases; systemic chemotherapy is rarely needed.
• Pitfalls:
  • Misdiagnosis: ALCL can mimic other lymphomas (e.g., classic Hodgkin lymphoma, diffuse large B-cell lymphoma with CD30 expression, anaplastic carcinoma) and non-lymphoma conditions. Careful pathological review is essential.
  • Inadequate biopsy: Relying on FNA or a small core biopsy can lead to misdiagnosis or delayed diagnosis.
  • Under-staging: Failure to perform comprehensive staging (e.g., PET-CT, bone marrow biopsy) can lead to inappropriate treatment.
  • Failure to consider BIA-ALCL: In patients with breast implants presenting with late seromas or masses.

Recent Updates

• Guidelines:
  • NCCN (National Comprehensive Cancer Network) Guidelines: Updated recommendations for T-cell lymphomas, incorporating BV+CHP as a preferred frontline regimen for systemic ALCL.
  • WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition): Further refines the classification of ALCL subtypes and introduces new entities based on molecular drivers.
• Evidence:
  • ECHELON-2 Trial (2018): Landmark phase III trial demonstrating superior 5-year progression-free survival (PFS) and overall survival (OS) with Brentuximab Vedotin + CHP compared to CHOP as frontline therapy for CD30+ peripheral T-cell lymphomas, including ALCL (predominantly ALK+). This has significantly changed the standard of care.
  • Emerging data on PD-1 inhibitors (nivolumab, pembrolizumab): Showing promise in relapsed/refractory ALK-negative PTCL, including ALCL.
  • Further understanding of BIA-ALCL: Continued research on epidemiology, pathogenesis, and optimal management strategies for BIA-ALCL, including registry data (e.g., PROFILE Registry).
• Controversies:
  • Optimal consolidation for high-risk ALCL: The role of upfront or high-dose chemotherapy with ASCT in first remission for high-risk systemic ALCL is still debated, particularly in the BV+CHP era.
  • Role of ALK inhibitors upfront: While effective in relapsed/refractory ALK+ ALCL, their role as part of frontline therapy (e.g., in combination with chemotherapy) is under investigation in clinical trials.
  • Management of very rare or atypical presentations: Optimal treatment for extremely rare variants or those with unusual resistance patterns.

Key References

• Guidelines:
  • National Comprehensive Cancer Network (NCCN) Guidelines: T-Cell Lymphomas. Available at NCCN.org.
  • World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition).
  • European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for diagnosis, treatment and follow-up of peripheral T-cell lymphoma.
• Studies:
  • Horwitz SM, O'Connor OA, Pro B, et al. Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma (ECHELON-2): A Randomized, Double-Blind, Phase 3 Trial. Lancet. 2019;393(10168):229-240.
  • Vasek M, et al. Breast implant-associated anaplastic large cell lymphoma: 2022 Update. Curr Opin Oncol. 2022;34(5):455-462.
• Reviews:
  • UpToDate: Anaplastic large cell lymphoma (ALCL): Clinical manifestations, pathologic features, and diagnosis.
  • UpToDate: Treatment of systemic anaplastic large cell lymphoma.
  • UpToDate: Primary cutaneous CD30-positive lymphoproliferative disorders.
  • Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon, France: IARC Press; 2017. (Note: 5th edition now available).